ARA-290

ARA-290, also published as Cibinetide, is catalogued here as: 11-amino-acid peptide derived from erythropoietin. Studied in a small pilot trial in adults with sarcoidosis-associated small-fibre neuropathy for symptom-score changes. Also called cibinetide, this peptide has been explored in a small clinical pilot involving people with small-nerve-fibre symptoms.

Human trial literature: The four-week randomized pilot in 22 patients reported greater improvement in the small-fibre neuropathy screening score with ARA-290 than placebo. A small exploratory study, not established treatment efficacy.

Human trial literature: Pain-inventory and fatigue scores improved similarly in both groups; no safety concerns emerged from the short clinical and laboratory assessments. These results do not establish long-term safety or broad pain relief.

When comparing published work, match the exact molecular identity, salt form and strength to the paper. Findings in cell or animal models describe those models only and do not establish outcomes in people. The reconstitution calculator converts vial content and diluent volume into concentration for laboratory preparation.

Proof Line Peptides lists ARA-290 as a vial in 10 mg, with pack sizes of 1, 3, 5 and 10. Prices are shown in Canadian dollars, and orders ship from Toronto by tracked Canadian service.

A lab report for ARA-290 is available on request. Proof Line Peptides does not display a report until it is matched to the exact compound and strength.

Shipped lyophilized (freeze-dried) and stable at room temperature in transit. Store sealed vials in the fridge or freezer on arrival. Once reconstituted, refrigerate. Anything not right? Our guarantee covers it.